bristol
To sponsor this category, click here | subscribe to this category RSS

Home » Archives for bristol

Bristol Ignores California Over AIDS Drug Price Flap

Wednesday, July 28th, 2010

Over the past few weeks, Bristol-Myers Squibb was implored to lower the price of its Reyataz AIDS drug, given the funding crisis facing a growing number of state ADAP programs, which provide AIDS and HIV drugs to the public ( see here ). Among those lobbying the drugmaker is the AIDS Healthcare Foundation, which this week banned Bristol reps from its 11,000 or so clinics ( back story )

Posted in: Regulatory | 0 Comments »
Read the full story

Bristol Ignores California Official Over AIDS Drug Price

Wednesday, July 28th, 2010

Over the past few weeks, Bristol-Myers Squibb was implored to lower the price of its Reyataz AIDS drug, given the funding crisis facing a growing number of state ADAP programs, which provide AIDS and HIV drugs to the public ( see here ). Among those lobbying the drugmaker is the AIDS Healthcare Foundation, which this week banned Bristol reps from its 11,000 or so clinics ( back story ). At least one California official, it turns out, has also beseeched Bristol, but has so far been ignored

Posted in: Regulatory | 0 Comments »
Read the full story

Former Bristol Execs Strike Deal On Financial Fraud

Tuesday, June 29th, 2010

Rick Lane and Frederick Schiff struck a deal in which they will avoid criminal prosecution for an alleged scheme to artificially inflate financial results reported by Bristol-Myers Squibb The former execs will pay a combined $400,000 to a shareholder settlement fund and, in return, criminal charges will be dropped under a deferred prosecution agreement with federal prosecutors in New Jersey. The charges actually get tossed in 12 months if they stick to the deal, which was approved today by US District Court Judge Faith Hochburg, and stay out of trouble.

Posted in: Pharma News | 0 Comments »
Read the full story

AIDS Group Pressures Bristol-Myers To Lower Price

Monday, June 7th, 2010

In its latest effort to lower the cost of HIV drugs, the AIDS Healthcare Foundation is now mailing postcards directly to the homes of Bristol-Myers Squibb employees in the Princeton, NJ, area – where the drugmaker has its main laboratory complex – that feature a picture of ceo Lamberto Andreotti stuffing a $20 bill into his pocket as many more bills fall out of the sky behind him ( read the text here ).

Posted in: Pharma News | 0 Comments »
Read the full story

Drug boosts survival in major skin cancer study (AP)

Saturday, June 5th, 2010

AP – Researchers have scored the first big win against melanoma, the deadliest form of skin cancer. An experimental drug significantly improved survival in a major study of people with very advanced disease.

Posted in: headlines | 0 Comments »
Read the full story

Bristol?s Big Win

Saturday, June 5th, 2010

The first day of the year’s biggest  cancer conference is turning into a big victory for Bristol-Myers Squibb as its immune-boosting drug delays death from melanoma, one of the hardest-to-treat tumors. The medicine, ipilimumab, could be a big help to patients like Sharon Belvin. She was on..

Posted in: headlines | 0 Comments »
Read the full story
No Image

Bristol-Myers Skin Cancer Drug Prolongs Survival

Saturday, June 5th, 2010

The Bristol drug uses a patient’s own immune system to fight skin cancer, boosts survival by 3.5 months.

Posted in: headlines | 0 Comments »
Read the full story

Earnings Scorecard: Bristol-Myers Squibb

Monday, May 17th, 2010

Zacks.com submits: Bristol-Myers Squibb Company ( BMY ) reported first-quarter 2010 earnings on April 29, 2010 that surpassed the Zacks Consensus Estimate by 4 cents. However, the company reduced its 2010 forecast prompted by costs associated with U.S. healthcare reform

Posted in: Pharma News | 0 Comments »
Read the full story
No Image

A Few Pharma Companies Speak to FDA Social Media Docket

Monday, February 8th, 2010

On January 29th new documents appeared in the FDA's docket that has been devised to collect commentary after the November 12-13 Part 15 meeting on social media and the Internet and medical product marketing.

Posted in: Regulatory, Social Media | 0 Comments »
Read the full story

Polluting the Literature with PAINs

Monday, February 8th, 2010

There’s an article out from a group in Australia on the long-standing problem of “frequent hitter” compounds. Everyone who’s had to work with high-throughput screening data has had to think about this issue, because it’s clear that some compounds are nothing but trouble.

Posted in: Clinical Trials | 0 Comments »
Read the full story